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Abstract
Background: Regular airway clearance by chest physiotherapy and/or exercise is critical to lung health in cystic
fibrosis (CF). Combination of cycling exercise and chest physiotherapy using the Flutter® device on sputum
properties has not yet been investigated.
Methods: This prospective, randomized crossover study compared a single bout of continuous cycling exercise at
moderate intensity (experiment A, control condition) vs a combination of interval cycling exercise plus Flutter®
(experiment B). Sputum properties (viscoelasticity, yield stress, solids content, spinnability, and ease of sputum
expectoration), pulmonary diffusing capacity for nitric oxide (DLNO) and carbon monoxide (DLCO) were assessed at
rest, directly and 45 min post-exercise (recovery) at 2 consecutive visits. Primary outcome was change in sputum
viscoelasticity (G’, storage modulus; G”, loss modulus) over a broad frequency range (0.1–100 rad.s− 1).
Results: 15 adults with CF (FEV1range 24–94% predicted) completed all experiments. No consistent differences
between experiments were observed for G’ and G” and other sputum properties, except for ease of sputum
expectoration during recovery favoring experiment A. DLNO, DLCO, alveolar volume (VA) and pulmonary capillary
blood volume (Vcap) increased during experiment A, while DLCO and Vcap increased during experiment B (all P < 0.05).
We found no differences in absolute changes in pulmonary diffusing capacity and its components between
experiments, except a higher VA immediately post-exercise favoring experiment A (P = 0.032).
Conclusions: The additional use of the Flutter® to moderate intensity interval cycling exercise has no measurable effect
on the viscoelastic properties of sputum compared to moderate intensity continuous cycling alone. Elevations in
diffusing capacity represent an acute exercise-induced effect not sustained post-exercise.
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Background
Cystic fibrosis (CF) is the most common genetic
life-limiting disease in Caucasians caused by abnormalities
in CF conductance transmembrane protein function. De-
pletion of airway surface liquid, dehydrated mucus, chronic
inflammation and infection contribute to accumulation of
secretions and subsequent progressive lung damage in CF
[1]. Regular airway clearance is therefore of critical import-
ance to lung health in CF. Exercise and chest physiother-
apy are accepted airway clearance techniques (ACT’s) in
CF, belonging to the current top ten research priorities [2].
There are a number of different ACT’s such as the active
cycle of breathing technique, high-frequency chest wall os-
cillations, positive expiratory pressure (PEP) and oscillatory
PEP. Oscillatory PEP with the Flutter® is equally effective
compared to other ACT’s [3] and has been shown to favor-
ably alter respiratory flow [4], to increase sputum expector-
ation [5] and to reduce sputum viscoelasticity [6, 7] in CF.
Exercise alone or in combination with chest physiother-
apy improves airway clearance and sputum expectoration
[6, 8], but the exact mechanisms are not fully understood.
Moreover, acute exercise is thought to facilitate mucocili-
ary clearance by increased shear stress on airway epithe-
lium and ciliary beat frequency as a result of an increased
ventilation [9], improved water content of mucus [10] and
increased trunk oscillations during weight bearing exer-
cises such as walking or running [11]. Recently, moderate
intensity exercise has been identified as ‘optimal training
intensity’ for individuals with mild to moderate CF lung
disease due to improvements in bronchodilation and pul-
monary diffusing capacity and prevention of airflow re-
striction compared to vigorously intense exercise [12].
Enhanced mucus clearance might potentially (at least in
part) result in an improvement in pulmonary gas diffusion.
The aim of this study was to compare a single bout of
moderate intensity cycling exercise incorporating a
breathing therapy device, the Flutter®, with a single bout
of moderate intensity cycling exercise alone on sputum
viscoelasticity (primary endpoint) and pulmonary diffus-
ing capacity in adults with CF. We hypothesized that the
combination of a high ventilation during cycling exercise
in combination with increased oscillatory shear stress
(Flutter®) yields greater improvements in sputum visco-
elasticity compared to cycling exercise alone.
Methods
Study design
We conducted a prospective, randomized, controlled
crossover trial (Clinicaltrials.gov, NCT02750722). Adults
with CF were invited to our laboratory facility on three
different occasions. At the first study visit, the patients
provided a sputum sample, performed pulmonary func-
tion testing and cardiopulmonary exercise testing (CPET).
At the second and third study visit, patients provided
sputum samples, performed pulmonary function testing
and, depending on randomization, performed either con-
tinuous cycling exercise at moderate intensity without
Flutter® (Experiment A, control condition) or moderate
intensity interval cycling exercise incorporating Flutter®
therapy (Experiment B, experimental condition). The
detailed exercise protocol including measurements and
assessments during study visit 2 and 3 are shown in Fig. 1.
Study participants
Individuals with CF were recruited from the Adult CF
Center at the University Hospital Zurich, Switzerland, be-
tween June 2016 and January 2017. Patients aged 18 years
and older with a confirmed diagnosis of CF able to provide
sputum samples were included. Exclusion criteria were as
follows: i) listing for lung transplantation or status post
lung transplantation, ii) chronic pulmonary infection with
Burkholderia cepacia complex, iii) unstable clinical condi-
tion (i.e., major hemoptysis or pneumothorax within the
last 3 months, acute pulmonary exacerbation [13], intra-
venous antibiotic treatment during the last 4 weeks,
change in pulmonary medication during the study period);
iv) cardiac arrhythmias with exercise and v) requirement
of additional oxygen with exercise. Ethical approval was
obtained from the Cantonal Ethics Committee of Zurich
(2015–00153), Switzerland. All patients provided written
informed consent.
Randomization
We used central randomization to randomly allocate pa-
tients to the different experimental conditions (Experiment
A or B). A person not involved in the study generated a list
of random numbers using the statistical software package
STATA (Version 12, StataCorp. 2012, College Station,
Texas, USA). The list consisted of 30 random numbers,
where even numbers represented the experimental condi-
tion ‘A’ and odd numbers the condition ‘B’. The order of the
experiments at study visit 2 and 3 was either ‘A-B’ or ‘B-A’.
At the first study visit, after written informed consent was
obtained, the principal investigator (TR) called the person
creating the list of random numbers to obtain information
on the order of the exercise experiments for visit 2 and 3,
respectively. The patient was immediately informed about
the testing order for the following study visits.
Assessments
All tests were scheduled at the same time of the day (+− 1 h
deviation) to avoid any potential impact of diurnal variation
on pulmonary function measurements [14]. The time period
between study visit 1 and 3 was 8 ± 2 days, respectively.
Patients were told to abstain from fatty meals (for 3 h),
caffeine-containing substances (for 4 h) and to avoid vigor-
ous physical exercise during the last 24-h prior to the study
visits, respectively. Moreover, patients were told to abstain
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from their regular inhalation and airway clearance therapy
on the day of the study visits. The following provides a short
description of assessments methods.
Sputum samples
At the beginning of each study visit, one sputum sample
was collected. At study visits 2 and 3, two additional
samples were collected immediately post-exercise and
again 45 min post-exercise, referred to as recovery (Fig. 1).
Sputum was gently expectorated and collected into sterile
and coded containers (cryotubes 5 mL, VWR). The con-
tainers were immediately stored at − 4 °C and transferred
on ice into a deep freezer (− 80 °C) after each study visit.
Sputum rheology
Rheological measurements were performed on a MCR 702
rheometer (Anton Paar, Austria) in parallel plate mode,
using sandblasted 25 mm diameter stainless steel plates
(PP25 S Anton Paar, Austria) and a gap size of 0.5 mm.
First, a frequency sweep was performed (0.1–100 rad s− 1,
γ = 1%) followed by an amplitude sweep (0.1–1000%, ω =
1 rad s− 1). The snap frozen sputum samples (− 80 °C) were
transferred to the fridge (4 °C) at least 6 h before the
measurement. The slowly thawed samples were then
transferred from the cryotubes to the lower measuring
plate using a 1 mL micropipette. The micropipette tips
were cut in the front with a scalpel to have a larger die,
thus minimizing shear on the sample. The upper plate was
slowly lowered onto the sputum, and a solvent trap
containing moist sponges was placed over the sample.
Prior to measurements, the sputum was let to rest for five
minutes. All measurements were performed temperature
controlled at 20 °C. Inertia calculations are based on equa-
tions reported by Ewoldt et al. [15].
The spinnability of sputum describes its ability to form fila-
ments, which provides valuable information about cohesion
Fig. 1 Experimental study design. fR, respiratory frequency; HR, heart rate; SpO2, oxygen saturation; V’CO2, carbon dioxide production; V’E, minute
ventilation; V’O2, oxygen consumption; VT, tidal volume. The grey shaded area represents the periods when the participants breathed through
the mouthpiece for metabolic cart measurements
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forces in the sputum [16]. At the end of each rheological
measurement, the upper plate was separated from the lower
plate at a constant velocity of 3.6 mm s− 1 [17], which was
filmed (iPhone 6, Apple) at 120 fps (Fig. 2a). The sputum
formed a filament between the separating plates. The separ-
ation distance at which the sample broke (‘spinnability’) was
extracted from the movie by counting the amount of frames
from the onset of separation until filament breaking.
To estimate sputum solids content, 0.25 mL aliquots of
sputum were filled in 1.5 mL HPLC vials (VWR,
Switzerland) and weighed with a high precision scale (Met-
tler AE 163, Mettler Toledo, Switzerland). The samples were
then dried for 24 h at 50 °C and a pressure of 100 mbar
using a vacuum drying oven (SalvisLab, Switzerland) and
subsequently weighed again. All rheological measurements
were done by a person (PB) who was blinded with respect to
the two different experimental conditions.
Ease of sputum expectoration was assessed on a 10 cm
visual analogue scale (0 = very difficult and 10 = very easy).
A blinded assessor, not involved in the study, measured
the distance for all scales after completion of all study
experiments.
Spirometry
Spirometry was always performed before diffusing capacity
measurements with the patient in sitting position using a
commercially available system (MasterScreen™ PFT Pro,
Jaeger, PanGas AG Healthcare, Switzerland) according to
American Thoracic Society/European Respiratory Society
Standards [18]. All tests were performed pre-bronchodilation
(i.e., withheld of short-acting bronchodilators and
anticholinergic drugs for at least 4 h, long-acting bronchodi-
lators for at least 12 h, and once-daily, long-acting broncho-
dilators for at least 24 h). We calculated percent-predicted
values for forced expiratory volume in 1 s (FEV1) using refer-
ence equations from Quanjer et al. [19].
Pulmonary diffusing capacity
Details on the methods can be found elsewhere [20]. In
brief, pulmonary diffusing capacity measurements were
done in triplicate at rest and for the measurements done
45 min post-exercise (visit 2 and 3). If intra-session repro-
ducibility criteria were not fulfilled additional measure-
ments were performed [21]. Two maneuvers were
performed immediately post-exercise (see Fig. 1 in the
publication). In general, a 5 min pause was done between
consecutive maneuvers to assure adequate elimination of
test gas from the lungs [22]. For the analysis, we used the
average value of the first two single-breaths tests for ma-
neuvers performed at rest and 45 min post-exercise, when
intra-session acceptability criteria were fulfilled [21]. If
intra-session acceptability criteria were not fulfilled [21],
the third single-breath test was considered and the average
of the two highest test results was used. For the measure-
ments immediately post-exercise (see Fig. 1 in the publica-
tion), the first test was used for statistical analysis. We
calculated percent-predicted values for diffusing capacity
for nitric oxide (DLNO) and carbon monoxide (DLCO),
pulmonary capillary blood volume (Vcap) and the
alveolar-capillary membrane diffusing capacity for carbon
monoxide (DMCO) according to references equations
published by Zavorsky et al. [21].
Fig. 2 Rheology and spinnability of cystic fibrosis sputum. (a) Spinnability of sputum was assessed at the end of rheological measurements by
lifting up the upper plate at a constant velocity of 3.6 mm s− 1. (b) Amplitude sweep (at 1 rad s− 1) showing a linear viscoelastic (LVE) regime up
to about 1% deformation. The dashed violet lines show the graphical determination of the dynamic yield point / stress. (c, d) Frequency sweeps
depicting G’ (storage modulus), G” (loss modulus) and η* (complex viscosity). The grey dashed lines represent the vertically shifted fitting curves
(fitting between 0.1–10 rad s− 1). The blue dashed lines in (b, c) indicate the calculated instrument inertia limit
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Cardiopulmonary exercise testing
Cardiopulmonary exercise testing (CPET) was performed
on a cycle ergometer (custo ec 3000e, custo med GmbH,
Ottobrunn, Germany) using the Godfrey Protocol [23].
The test started with a three-minute rest period followed
by three-minutes of unloaded pedaling at 60–70 rpm.
Afterwards, the workrate (W, watts) was increased every
minute according to the patient’s height: 10 W (< 120 cm),
15 W (120–150 cm) or 20 W (> 150 cm) [23]. The incre-
ment was individually adapted for patients with severely
reduced lung function (i.e., FEV1 < 30% predicted). After
the patients had reached their maximal exercise perform-
ance, he/she rested for another three-minutes on the cycle
ergometer (recovery phase).
The metabolic cart (Metalyzer®, Cortex Biophysik GmbH,
Leipzig, Germany) was calibrated with gases of known stand-
ard concentrations before each test. Heart rate was measured
with a Polar heart rate monitor (Polar RS400, Polar Electro,
Oy, Kempele, Finland) and oxygen saturation (SpO2) was
continuously measured at the earlobe (Nonin® Xpod® Pure-
SAT®,Nonin Medical, Inc, USA). Ratings of perceived exer-
tion and dyspnea were evaluated at peak exercise by means
of a 0–10 Borg scale [24]. One of the following criteria had
to be fulfilled to ensure the test was maximal: 1) plateau in
oxygen consumption (V’O2) despite an increase in work-
rate; 2) peak heart rate over 85% of predicted [25], 3) re-
spiratory exchange ratio (RER) > 1.05, 4) peak ventilation
exceeded predicted maximum voluntary ventilation (cal-
culated as FEV1 × 35) and 5) subjective impression of the
supervisor. Maximal heart rates were used to calculate ex-
ercise intensities (50 and 75% of peak heart rate) for the
cycling experiments at visit 2 and 3.
Patient-reported health status
Patient-reported health status was assessed with the Feeling
Thermometer. The Feeling Thermometer is part of the
EQ-5D, a common instrument used for healthy economic
analyses and established by the EuroQol group [26]. The
Feeling Thermometer is a modified visual analogue scale in
form of a thermometer. The instrument has marked
intervals from 0 (worst health state ) to 100 (perfect health).
We used the instrument to evaluate whether patients were
in a stable health condition during the study.
Anthropometry
We measured each patient’s height to the nearest 0.1 cm
using a stadiometer (Seca). Body weight was measured
to the nearest 0.5 kg at each study visit using a balanced
scale (Seca, Model 791, Vogel & Halke).
Moderate cycling exercise with and without Flutter® therapy
At study visit 2 and 3, moderate intensity cycling exercise
at 75% of the peak heart rate achieved during CPET was
performed either continuously (experiment A) or in
4-min intervals (experiment B) interspersed with 2-min
resting periods, during which breathing maneuvers were
performed using the Flutter® (see Fig. 1). At rest and dur-
ing cycling (minute 12–16′), patients respired through a
mouthpiece connected to the metabolic cart to measure
respiratory gases (Fig. 1). Heart rate was continuously
monitored with a chest belt and heart rate monitor
(Polar RS400, Polar Electro, Oy, Kempele, Finland)
and SpO2 with an earlobe pulse oximeter (Nonin®
Xpod® PureSAT®,Nonin Medical, Inc, USA), respect-
ively. The average value during 3 min at rest and dur-
ing minutes 14–16 during exercise (steady-state
conditions) were used for data analyses.
Flutter® breathing therapy
The Flutter® (VRP1, Eur. Patent. No: 0337990) is an airway
clearance device providing oscillations during exhalation
and vibrations of the airways aiming to facilitate mucus
clearance in the airways. The Flutter® is a pipe like device
with an oscillating stainless steel ball and a perforated
cover. The device produces positive expiratory pressure
and the angle at which the Flutter® is held determines the
oscillation frequency of 6 to 20 Hz [27]. Exhalation through
the Flutter® causes oscillation of the steel ball and produces
rhythmic variations in positive expiratory pressure of 10 to
25 cm H2O [28, 29]. Flutter® therapy increases peak expira-
tory flow and creates an expiratory airflow bias in CF [6],
initiating mucociliary clearance mechanisms.
During experiment B, 6–10 breathing maneuvers were
performed during each of the 2 min resting periods (Fig. 1)
without forced expiratory technique. The breathing maneu-
vers started with a slightly deep inspiration, a 2–3 s
end-inspiratory pause and a forced expiration lasting about
5 s while the patient was sitting on the cycle ergometer
without pedaling. The Flutter® device was kept in neutral
(horizontal) position to maximize the oscillation amplitude
and to target a frequency range of 10–15 Hz [29], optimal
for mucus clearance. All patients received proper instruc-
tions on the use of the device at the first study visit. Patients
without experience with the Flutter® received a device at
the end of visit 1 enabling practice at home before the
second study visit.
Statistical analysis and sample size calculation
All statistical analyses were performed with the statistical
software package SPSS version 23 (IBM Corp. Armont, NY,
USA). Descriptive data are presented as median (interquar-
tile range, IQR), mean ± SD or N (%). We used the
non-parametric Friedman Test to test for differences in
resting (pre-exercise) sputum properties, spirometry,
pulmonary diffusing capacity and patient-reported health
status between the three study visits. Differences in out-
come variables between the three different time points
(pre-exercise; immediately post-exercise and 45 min
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post-exercise, respectively) during each experimental condi-
tion were analyzed with the non-parametric Friedman test
followed by a Wilcoxon-signed rank test, if changes over
time in the Friedman test were significant (P < 0.05). We
calculated absolute changes between the different
time-points (i.e., post-exercise minus pre-exercise and
45 min post-exercise minus pre-exercise values) and
compared the two experimental conditions using the
non-parametric Mann-Whitney-U test. The level of statis-
tical significance was set as P < 0.05.
No previous study has investigated changes in sputum
viscoelasticity following a combination of cycling and
Flutter® using the same instruments as in our study from
which we could derive means and standard deviations
(SD’s) and on which we could base our power calcula-
tions. However, two previous studies using randomized
crossover designs comparing i) an acute bout of cycling
and treadmill exercise versus no exercise [11] or ii)
Flutter® therapy with autogenic drainage [7] were able to
demonstrate significant changes in sputum viscoelasti-
city in 14 individuals with CF in each study. We there-
fore aimed to include 16 patients in our study.
Results
Baseline patient characteristics are shown in Table 1
(N = 16).
During the study, one female patient requiring oral anti-
biotic therapy for treatment of a pulmonary exacerbation
and was excluded from the analyses. All other patients
completed all assessments without complications. There
were no differences in pre-exercise sputum properties, pul-
monary function data and patient-reported health status
between the three study visits, respectively (Additional file 1:
Table S1). Cardiorespiratory variables during exercise were
comparable between both experiments (Additional file 2:
Table S2), whereas patients had a higher respiratory fre-
quency during experiment A compared to B (P < 0.001).
All patients were able to provide sputum samples at
the requested time points during the study. 13/15
patients had previous experience using Flutter®, but only
two were using the Flutter® on a regular basis.
CF sputum viscoelasticity and spinnability
The average of all sputum samples (n = 45) obtained at
rest during each of the three visits showed spinnability
(Fig. 2a) and viscoelastic behavior (Fig. 2b-d) characteris-
tic for CF sputum [7, 30–32]. Details can be found in
the online supplements (Additional file 3: Table S4). At
high frequencies (ω > 10 rad s− 1) G’ and G” as well as η*
(complex viscosity) and the phase angle increased due to
instrument inertia, which causes artifacts in the sample
signal. Consequently, the analysis of sputum viscoelasti-
city (G’ and G”) was restricted to an angular frequency
of 10 rad s− 1. Instrument inertia is further debated in
the Discussion section and online supplements.
Changes in sputum rheological properties
Table 2 shows changes in sputum properties for each ex-
perimental condition. No time-course changes were found
during either experiment A or B, except for sputum solids
content during experimental condition A (P = 0.038). Indi-
vidual raw data for G’ at 1 and 10 rad s− 1 are shown in
Additional file 4: Figure S1 and Additional file 5: Figure S2
in the online supplements. In the experimental condition
A, one study participant had very high values for G’ at 1
and 10 rad s− 1 immediately post-exercise. Of note, there
was no technical problem during the rheological measure-
ments, but the sputum sample was purulent and thick. A
summary of all sputum rheological data excluding this par-
ticular participant is shown in Additional file 6: Table S3 in
the online supplements.
No differences in sputum rheological properties (viscoelas-
tic moduli G’ and G”, yield stress, solids content) were found
between experiments (Table 3), except differences in sputum
spinnability comparing pre- versus 45′ post-exercise values
between experiments. During recovery (absolute change,
pre- vs. 45 min post-exercise), we noticed differences in pa-
tient reported ease of sputum expectoration, favoring experi-
mental condition A (P= 0.016).
Changes in pulmonary diffusing capacity
Individual raw data for DLNO, DLCO, VA and Vcap at
different time points during experiments A and B are
Table 1 Patient baseline characteristics
Variables
N 16
Sex (male/female) 7/9
Age (years) 23 (22, 25)
BMI (kg m− 2) 20 (18, 21)
Cystic fibrosis-related diabetes (N (%)) 8 (50)
Pancreatic insufficiency (N (%)) 13 (81)
Chronic Pseudomonas aeruginosa infection (N (%)) 7 (44)
FEV1 (% predicted) 52 (43, 72)
DLNO (% predicted) 59 (51, 73)
DLCO (% predicted) 82 (69, 86)
V’O2peak (mL kg
− 1 min− 1) 32.0 (30.3, 34.4)
Mechanical power (W kg− 1) 2.9 (2.3, 3.1)
HRpeak (beats min
− 1) 167 (163, 179)
RER 1.20 (1.15, 1.26)
Data are median (IQR) or N (%). BMI body mass index, CF cystic fibrosis, DLCO
diffusing capacity of the lung for carbon monoxide, DLNO diffusing capacity of
the lung for nitric oxide, FEV1 forced expiratory volume in one second,
HRpeak peak heart rate, RER respiratory exchange ratio, V’O2peak peak
oxygen consumption
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shown in Additional file 7: Figure S3 and Additional file 8:
Figure S4 in the online supplements. Time course changes
in pulmonary diffusing capacity were observed during both
experiments, while changes in DLNO and VA were only ob-
served in experimental condition A (Table 2). No differ-
ences in pulmonary diffusing capacity were found between
the two experimental conditions (Table 3), except a higher
VA comparing post-exercise and pre-exercise changes
favoring experiment A (P = 0.032).
Discussion
This randomized controlled crossover study investigated
acute effects of moderate intensity continuous cycling
exercise versus interval cycling exercise incorporating
the Flutter® device on sputum viscoelasticity (primary
endpoint) and pulmonary diffusing capacity in adults
with CF. This study provides three important findings.
First, the addition of Flutter® to moderately intense sta-
tionary cycling has no measurable effect on sputum
viscoelastic properties compared to stationary cycling
alone. Second, our results highlight experimental chal-
lenges to simulate ‘coughing’ (i.e., 100 rad s− 1 measure-
ments or generally high frequency measurements) in a
shear rheological setup due to instrument inertia effects.
Third, the increase in pulmonary diffusing capacity over
time reflects an acute exercise-induced effect, not
sustained post-exercise.
Sputum rheological properties and exercise
In the present study, we found no differences in sputum
viscoelasticity between the two experimental conditions,
thus rejecting our initial hypothesis. Two previous studies
reported altered sputum viscoelasticity after an acute bout
of treadmill exercise or Flutter® and treadmill exercise com-
pared to resting breathing in adults with CF [6, 11]. Tread-
mill but not cycling exercise reduced sputum viscoelasticity
and trunk oscillations during treadmill running/walking
have been postulated as a possible underlying mechanism
[11]. One could argue that the chosen exercise mode in our
study was not sufficient to improve viscoelastic properties
of sputum in our patients and/or that the magnitude of ef-
fect from Flutter® was not large enough to produce greater
changes in sputum viscoelastic properties compared to
cycling alone. During exercise, our patients achieved ap-
proximately 47–49% of their maximal minute ventilation
(90–97% of their maximal tidal volumes and 50–55% of
their maximal respiratory frequencies, see Additional file 2:
Table S2) suggestive of a high ventilatory demand. Higher
exercise intensities (e.g., 90% of maximal heart rate) may in-
duce significant airway narrowing [12] unlikely to be main-
tained by many patients when exercising for longer periods,
in particular, in patients with advanced lung disease. With
respect to Flutter®, our patients performed 6–10 breathing
maneuvers during each of four cycles. Higher volumes of
Flutter® therapy (6 cycles à 15 breaths) combined with
huffing and coughing (forced expiration technique, FET)
improved sputum viscoelasticity compared to resting
breathing in adults with CF [6]. It is important to note that
we deliberately did not follow existing CF physiotherapy
recommendations [27] suggesting to individually determine
the angle of the Flutter® along with the performance of
forced expiratory maneuvers. In this study, we were mainly
interested in mechanistic effects of airway oscillations on
sputum viscoelasticity [7] on top of high ventilation during
exercise. We did not implement forced expiratory maneu-
vers due to potential interference with our cycling protocol
and pulmonary gas exchange measurements. The authors
hypothesize that a more intense Flutter® therapy, together
with individual adaptation of the Flutter® angle, but not the
lack of forced expiratory maneuvers, could explain the ab-
sence of additional effect in our study. Given the fact that
positive expiratory pressure and oscillations are thought to
mechanically impact on biophysical properties of mucus
(i.e., reduction of viscoelasticity), huffing and coughing
following Flutter® maneuvers assist in mobilization and
transport of secretions from peripheral to central airways,
but should not substantially change viscoelastic properties
of sputum in addition. This hypothesis is supported by an
in vitro experiment demonstrating that Flutter® oscillations
alone augment sputum elasticity after 15 and 30 min,
respectively [7].
It is important to mention that in comparison to our
experimental study design, the study by Dwyer et al. [6]
compared Flutter® therapy with resting breathing (no inter-
vention), which likely increases the chance to observe effects
between experimental conditions. Nevertheless, given the
high variability of sputum properties [33] and differing intra-
and interindividual responses to airway clearance therapy, a
“no intervention” visit would have probably provided further
insights into within-patient treatment responses.
Interestingly, and in line with findings by Dwyer et al.
[11], ease of sputum expectoration was higher during re-
covery from continuous cycling versus cycling exercise with
Flutter®. This suggests that patients perceive the benefit of
airway clearance therapy not immediately but during recov-
ery from exercise. However, the clinical meaningfulness of
these findings cannot be interpreted due to the lack of a
minimal important difference for the visual analogue scale.
Rheological measurements and inertia
We observed occurrence of inertia at high frequencies, caus-
ing experimental artifacts (see Additional file 9 for further
discussion). King and Macklem suggested first that sputum
rheology at high frequency simulates cough studying dog
tracheal mucus [34]. The concept was then further
elaborated suggesting that low frequency (1 rad s− 1)
deformations are relevant when simulating ciliary
transport [35] whereas high frequency (100 rad s− 1)
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deformations are more characteristic for cough clear-
ance [36]. The 1 rad s− 1 / 100 rad s− 1 concept was
initially elaborated using active microrheology but was
later applied in shear rheology testing [6, 11, 37, 38].
We found a strong increase in moduli (G’, G”) and phase
angles at frequencies > 10 rad s− 1 (Fig. 2c and d,
Additional file 10: Figure S5a) and observed that sample
torques deviated from the electrical torques (Additional
file 10: Figure S5b), both strong indicators for inertia. The
deviation of sample torque from electrical torque due to
inertia is schematically represented in torque vector draw-
ings in Additional file 10: Figure S5c. Also, we calculated
the theoretical inertia limit of the rheometer, which agreed
well with the observed onset of inertia. Further proof is
obtained comparing our results to other findings that
show a continuous trend of the dynamic moduli up to
50 Hz (≈ 314 rad s − 1) using passive microrheology [32],
which is not affected by inertia at frequencies below
1 MHz [39]. Data generated in previous studies using
shear rheology at 100 rad s− 1 also showed signs of inertia
[6, 11, 37, 38], revealed by a substantially increased loss
modulus G” or complex modulus (G*) and high tan δ
values compared to those measured at 1 rad s− 1. Future
rheology measurements with sputum should be carefully
checked for inertia, as in the worst-case scenario, false
positive or false negative outcomes occur. We propose
restricting frequencies to 10 rad s− 1 to simulate the high
frequency behavior of sputum in shear rheology.
Pulmonary diffusing capacity and exercise
In the present study, DLNO and DLCO increased during
continuous cycling exercise, whereas interval cycling exercise
interspersed with use of the Flutter® increased only DLCO
but not DLNO, most likely due to the absence of increase in
VA. It is well known that DLNO, DLCO, and Vcap increase
linearly during exercise with respect to cardiac output [40].
In our study, continuous cycling increased post-exercise
DLNO by about 5%, but the effect was not sustained during
recovery. We extend previous findings reporting a remark-
able increase in DLNO (39 ± 8% from rest using rebreathing
measurements) during moderate intensity cycling exercise in
CF adults, with the authors questioning the duration of
beneficial effects [12]. Our data demonstrate that increase in
DLNO is (only) an acute, exercise-induced effect, most likely
the result of increased VA and subsequently greater surface
area for diffusion rather than improved mucociliary clearance
mechanisms such as improved sputum hydration and/or
viscoelastic properties.
This study has limitations. First, we did not measure
expiratory flow during exercise [6, 11] to evaluate whether
our experiments were sufficient to create an expiratory
airflow bias, a mechanism potentially improving mucocili-
ary clearance. Furthermore, the sputum was sheared at
50 Pa in simple shear experiments prior to spinnability
measurements. The shear homogenized the samples, theor-
etically disrupting sputum microstructure, which could
have caused the comparably low spinnability values. Finally,
our study patient cohort was small, limiting the
generalizability of our findings to the overall CF population.
Conclusions
We conclude that the addition of Flutter® to moderate
intensity interval cycling exercise has no measurable
effect on the viscoelastic properties of sputum compared
to moderate intensity continuous cycling alone. The
higher pulmonary diffusing capacity represents an acute
exercise-induced effect not sustained post-exercise.
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